Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B.
about
Charting the NF-κB pathway interactome mapINK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappaBRespiratory syncytial virus-inducible BCL-3 expression antagonizes the STAT/IRF and NF-kappaB signaling pathways by inducing histone deacetylase 1 recruitment to the interleukin-8 promoterIdentification and characterization of BCL-3-binding protein: implications for transcription and DNA repair or recombinationI kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA bindingBCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteinsI kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity.A novel NF-kappa B complex containing p65 homodimers: implications for transcriptional control at the level of subunit dimerizationNuclear uptake control of NF-kappa B by MAD-3, an I kappa B protein present in the nucleusBCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcriptionIkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase.Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation.Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IkappaB protein family.I kappa B alpha-mediated inhibition of v-Rel DNA binding requires direct interaction with the RXXRXRXXC Rel/kappa B DNA-binding motifThe NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa BThe bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent mannerPurification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcriptionNF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like moleculeThe ankyrin repeat as molecular architecture for protein recognitionRegulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factorsT cell leukemia-associated human Notch/translocation-associated Notch homologue has I kappa B-like activity and physically interacts with nuclear factor-kappa B proteins in T cellsThe putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transitionRegulation of the Adaptive Immune Response by the IκB Family Protein Bcl-3NF-κB, the first quarter-century: remarkable progress and outstanding questionsCapture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23Regulation of serum amyloid A protein expression during the acute-phase responseGadd45 proteins as critical signal transducers linking NF-kappaB to MAPK cascadesConstitutive NF-kappa B activity in neuronsTumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activationDNA binding alters the protease susceptibility of the p50 subunit of NF-kappa B.Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis.A novel role for IkappaBzeta in the regulation of IFNgamma productionBasal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network.Isolation of a novel interleukin-1-inducible nuclear protein bearing ankyrin-repeat motifs.A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei.Intragenic dominant suppressors of glp-1, a gene essential for cell-signaling in Caenorhabditis elegans, support a role for cdc10/SWI6/ankyrin motifs in GLP-1 function.Historical review of lymphomas.The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites.In vivo control of NF-kappa B activation by I kappa B alpha.Neoplastic transformation of T lymphocytes through transgenic expression of a virus host modification protein.
P2860
Q21134745-01E06B50-1A0E-4366-86E6-0BFA741FD963Q22009941-E665601D-98E3-4F9D-9FBC-73ABB0139B2FQ24296927-B170741A-31A4-4B78-92F9-CA16BFECFA55Q24301013-20A40496-483E-471F-A334-6CD94C3F7BF6Q24307786-9F5B14CC-B221-4372-A389-62D18ED3716DQ24315909-F0C2B81F-D3C6-4C99-8053-25B512678510Q24318573-4A3FDD77-14B7-47CF-81E8-229D43BF1AE0Q24320246-DC76C328-F7CC-4D63-BE38-2C18970676A9Q24337591-4D4043F6-630D-42C9-883B-06F41F9F1DCFQ24338268-7DB64A27-1040-47EE-9959-B0011ED9816BQ24532221-1ACECA5D-54A3-44BD-91D6-A90966EEF50AQ24532251-8DC2E9E5-9DE5-45EF-B547-8457CD167093Q24535966-B0084878-DA96-400C-BDD8-09AABEBF66E5Q24561403-15B30E71-B0CF-443B-A84A-1EF1E40EEC79Q24564833-B9094AC2-2DFC-4230-81E6-DD1E6CB4D80CQ24604635-62127070-CF9F-418E-818D-5CAD6A533550Q24613327-03CF953F-A33D-420D-B69E-D8A4C4C28DA0Q24629772-C7E85FD7-1073-45F9-837E-71B69B1C4BCEQ24646394-9566A92B-F08E-498E-A87B-40A34EEE8749Q24651506-852F8E7B-F73C-4528-9F94-33908F71EE8FQ24678251-3AB929B1-5924-48A0-9C6E-16450EACB1C3Q24746253-3F6D1917-F659-4272-9161-4CFEEB99CDCBQ26749588-C7955E50-8C30-4464-A03B-792CDAA3D3B4Q26822516-84296C66-4C72-4A24-9A8C-22B21EE1ED48Q28109583-857569C0-75E0-4FBC-BD5B-B66929B69CBCQ28281545-94810863-E45E-4D30-A875-497FEDCF7C1FQ28388105-63C12F3E-47DA-4091-A934-B5B763EF6E3EQ28582881-37C80D8E-CA58-4EA0-A2CA-DA5BA8C4E2B8Q28776205-C14196E2-4391-45A0-8F49-B631B12216F9Q30421431-307A9FC0-A136-4FA2-8E68-A3946B8DCEA4Q30847621-C40253A1-1F8F-4011-87BE-A38F1B815BDDQ33496727-B1356C66-D567-4A3E-AC9F-7FAB9E0474E7Q33508814-62204839-6A96-4244-9508-E65B60468782Q33940319-9510A271-BB8D-49BF-A13E-683495BAFB48Q33947106-48FC9670-AE94-4B44-8B2F-1B3CE114F49BQ33961968-F987004F-07D8-4DAF-882B-34F295D8839DQ33962044-135F3463-A97F-47EE-B8E0-8BEEC750EC0FQ34061332-2EE66507-EEAC-42CF-9196-434263C4F3C4Q34069959-58FCB73A-44C9-42DE-A88E-A95084830AF6Q34256167-5DB15202-C119-476A-B4D5-8C9D15C7B948
P2860
Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@ast
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@en
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@nl
type
label
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@ast
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@en
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@nl
prefLabel
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@ast
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@en
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@nl
P2093
P356
P1433
P1476
Candidate proto-oncogene bcl-3 ...... anscription factor NF-kappa B.
@en
P2093
Scheidereit C
Wulczyn FG
P2888
P304
P356
10.1038/358597A0
P407
P577
1992-08-01T00:00:00Z
P6179
1036876254